BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-09
195 industry Phase 2/3 trial readout(s) and 48 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-09 est. | P1/P2 | CelaCare Technologies, Inc. | NCT03250923 CelAgace™ OraRinse Solution for Treatment of Candidiasis | Candidiasis, Oral | unknown | 15 |
| 2024-09 est. | P2 | ISA Pharmaceuticals | NCT03669718 A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | Squamous Cell Carcinoma of the Oropharynx; HPV16 Positive | unknown | 194 |
| 2024-09 est. | P2 | Aphios | NCT03806478 Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease | Dementia; Alzheimer Disease 1; Alzheimer Disease 2; Alzheimer Disease 3 | unknown | 60 |
| 2024-09 est. | P3 | Cirius Therapeutics, Inc. | NCT03970031 A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH | Type2 Diabetes; NASH - Nonalcoholic Steatohepatitis; Nonalcoholic Steatohepatitis; Non-Alcoholic Fat | unknown | 1800 |
| 2024-09 est. | P2 | APRINOIA Therapeutics, LLC | NCT04141150 Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects | Alzheimer's Disease; Mild Cognitive Impairment Due to Alzheimer's Disease; Healthy Volunteers | unknown | 130 |
| 2024-09 est. | P1/P2 | Sorrento Therapeutics, Inc. | NCT04316442 Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis | Light Chain (AL) Amyloidosis | unknown | 60 |
| 2024-09 est. | P2 | Philogen S.p.A. | NCT04362722 Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients | Carcinoma, Basal Cell; Carcinoma, Cutaneous Squamous Cell | unknown | 40 |
| 2024-09 est. | P2 | Celltex Therapeutics Corporation | NCT04428801 Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 | COVID-19 | unknown | 200 |
| 2024-09 est. | P1/P2 | AVEM HealthCare | NCT04798716 The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 | Covid19; Novel Coronavirus Pneumonia; Acute Respiratory Distress Syndrome | unknown | 55 |
| 2024-09 est. | P2 | Audion Therapeutics BV | NCT05061758 A Trial of LY3056480 in Patients With SNLH | Sensorineural Hearing Loss | withdrawn | |
| 2024-09 est. | P2 | Poxel SA | NCT05146284 Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Adrenomyeloneuropathy | withdrawn | |
| 2024-09 est. | P2 | Poxel SA | NCT05200104 Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | ALD (Adrenoleukodystrophy) | withdrawn | |
| 2024-09 est. | P2 | Engrail Therapeutics INC | NCT05481905 ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures | Focal Epilepsy | withdrawn | |
| 2024-09 est. | P2 | AlgoTherapeutix | NCT05593614 Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) | Chemotherapy-induced Peripheral Neuropathy | active not recruiting | 276 |
| 2024-09 est. | P1/P2 | GreenLight Biosciences, Inc. GLRE | NCT05602961 A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster | COVID-19 | withdrawn | |
| 2024-09 est. | P2 | OrsoBio, Inc | NCT05665751 A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance | Insulin Resistance | unknown | 76 |
| 2024-09 est. | P3 | Biocad | NCT05800327 A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously a | Rheumatoid Arthritis | active not recruiting | 261 |
| 2024-09 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05859373 To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemora | Non-small Cell Lung Cancer | unknown | 78 |
| 2024-09 est. | P2 | Repurposed Therapeutics, Inc. | NCT05886660 Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance | Motion Sickness, Space; Motion Sickness; Sea Sickness | unknown | 30 |
| 2024-09 est. | P1/P2 | Shanghai Cell Therapy Group Co.,Ltd | NCT05944185 Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors | Advanced Solid Tumor | unknown | 42 |
| 2024-09 est. | P2 | Carmell Therapeutics Corporation | NCT06258499 Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis | Foot Deformities | withdrawn | |
| 2024-09 est. | P1/P2 | LiteVax BV | NCT06294262 Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine | Vaccination Reaction | unknown | 84 |
| 2024-09 est. | P2 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | NCT06367114 Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltratio | Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | 50 |
| 2024-09 est. | P2 | Hanlim Pharm. Co., Ltd. | NCT06434792 Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | unknown | 96 |
| 2024-09 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06566248 A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary | Chronic Hepatitis B | unknown | 90 |
| 2024-09 est. | P3 | Clover Biopharmaceuticals AUS Pty CBPHF | NCT06567457 Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults | COVID-19 | withdrawn | |
| 2024-09-01 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04942067 APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma; Amyloidosis | unknown | 108 |
| 2024-09-01 | P1/P2 | GAIA BioMedicine Inc. GAIA | NCT05207371 Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC | Cell Therapy; NSCLC | terminated | 22 |
| 2024-09-01 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT05446883 QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | METASTATIC CERVICAL CANCER | unknown | 498 |
| 2024-09-01 est. | P2 | SpineX Inc. | NCT05720208 Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled Trial | Cerebral Palsy | unknown | 60 |
| 2024-09-01 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT05753865 A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | Advanced Breast Cancer | unknown | 454 |
| 2024-09-01 | P2 | MedRegen LLC | NCT05844527 Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients | Wound of Skin; Abdominal Wound | completed | 10 |
| 2024-09-02 | P1/P2 | GlaxoSmithKline | NCT05480800 A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever | Salmonella Infections | completed | 155 |
| 2024-09-02 | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06058000 A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 120 |
| 2024-09-02 | P2 | Cutia Therapeutics(Wuxi)Co.,Ltd | NCT06194188 A Phase 2 Clinical Study of CU-20401 | Efficacy and Safety | completed | 108 |
| 2024-09-03 | P1/P2 | Achilles Therapeutics UK Limited | NCT03997474 ATL001 in Patients With Metastatic or Recurrent Melanoma | Melanoma | terminated | 13 |
| 2024-09-03 | P3 | Hoffmann-La Roche | NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration | completed | 1036 |
| 2024-09-03 | P2 | Bausch Health Americas, Inc. | NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis | Ulcerative Colitis | completed | 322 |
| 2024-09-03 | P3 | Prokidney PROK | NCT05286853 A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease | Type 2 Diabetes Mellitus; Chronic Kidney Diseases | withdrawn | |
| 2024-09-03 | P3 | AbbVie ABBV | NCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around | Perioral Lines | completed | 198 |
| 2024-09-03 | P2 | Insmed Incorporated INSM | NCT06101823 Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) | Atopic Dermatitis | completed | 50 |
| 2024-09-04 | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT04168385 MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study | Cholestatic Liver Disease | completed | 52 |
| 2024-09-04 | P2 | Lumos Pharma | NCT04614337 Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) | Growth Hormone Deficiency | completed | 104 |
| 2024-09-04 | P2 | BeiGene | NCT05014815 Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC); Nonsmall Cell Lung | completed | 272 |
| 2024-09-04 | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT05107128 A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | Huntington's Disease | completed | 189 |
| 2024-09-04 | P1/P2 | Artax Biopharma Inc | NCT05725057 Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis | Psoriasis; Plaque Psoriasis | completed | 31 |
| 2024-09-04 | P3 | Alfasigma S.p.A. | NCT05785611 A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | Axial Spondyloarthritis | active not recruiting | 495 |
| 2024-09-04 | P3 | Dong-A ST Co., Ltd. | NCT05842408 Clinical Trial of DA-5212 in Patients with Functional Dyspepsia | Functional Dyspepsia | completed | 384 |
| 2024-09-04 | P2 | Neurogastrx, Inc. | NCT06500429 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist | Overweight and Obesity; Healthy | completed | 120 |
| 2024-09-05 | P3 | Merck Sharp & Dohme LLC MRK | NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastat | Lung Neoplasms; Non-Small-Cell Lung Carcinoma | terminated | 1264 |
| 2024-09-05 | P3 | Eli Lilly and Company LLY | NCT05074420 A Study of Baricitinib (LY3009104) in Children With COVID-19 | Covid19; Corona Virus Infection | terminated | 6 |
| 2024-09-05 | P3 | Takeda TAK | NCT05707351 A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A | Hemophilia A | completed | 37 |
| 2024-09-05 | P2 | Alto Neuroscience ANRO | NCT05712187 Phase 2b Study of ALTO-100 in MDD | Major Depressive Disorder | completed | 301 |
| 2024-09-05 | P3 | Boryung Pharmaceutical Co., Ltd | NCT05930028 A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia | Essential Hypertension; Primary Hypercholesterolemia | completed | 148 |
| 2024-09-05 | P2/P3 | Atom Therapeutics Co., Ltd | NCT06276556 Extension Study of ABP-671 in Participants With Gout | Gout | terminated | 43 |
| 2024-09-06 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Agitation in Patients With Dementia of the Alzheimer's Type | terminated | 1197 |
| 2024-09-06 | P2 | Hutchmed HCM | NCT04579679 Open-Label Surufatinib in European Patients With NET | Neuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NET | terminated | 78 |
| 2024-09-06 | P2 | UCB Biopharma SRL | NCT04658186 A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease | Early-stage Parkinson's Disease | completed | 496 |
| 2024-09-06 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05009290 A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical | terminated | 391 |
| 2024-09-06 | P1/P2 | Hutchmed HCM | NCT05077384 Open-label Study of Surufatinib in Japanese Patients | Neuroendocrine Tumors; Non-hematologic Malignancy | completed | 36 |
| 2024-09-06 | P1/P2 | MeiraGTx, LLC MGTX | NCT05603312 A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants | Parkinson's Disease | completed | 14 |
| 2024-09-06 | P3 | Sanofi SNY | NCT05878093 Dupilumab in Chinese Adult Participants With CRSwNP | Chronic Rhinosinusitis With Nasal Polyps | completed | 63 |
| 2024-09-06 | P3 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | NCT06314724 Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines | Varicella | completed | 642 |
| 2024-09-09 | P3 | SFJ Pharmaceuticals, Inc. | NCT04286438 Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure | Hemorrhage; Urgent Surgery; Invasive Procedure | completed | 226 |
| 2024-09-09 est. | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT04992858 Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations | Advanced NSCLC | withdrawn | |
| 2024-09-09 | P3 | AstraZeneca AZN | NCT05274815 Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma | Asthma | completed | 305 |
| 2024-09-09 | P3 | Marinus Pharmaceuticals | NCT05323734 Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | Tuberous Sclerosis Complex | completed | 129 |
| 2024-09-09 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06054698 Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects | Overweight or Obesity | completed | 61 |
| 2024-09-10 | P3 | 3D Medicines (Sichuan) Co., Ltd. | NCT03478488 Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC | Biliary Tract Neoplasms | completed | 472 |
| 2024-09-10 | P2/P3 | Sage Therapeutics | NCT05366751 A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | Essential Tremor | terminated | 97 |
| 2024-09-10 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT05643508 A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemi | Hypertension; Hyperlipidemias | completed | 214 |
| 2024-09-10 | P2 | Medibiofarma S.L. | NCT05940558 Safety and Efficacy of MBF-118 in Patients with Crohn Disease | Crohn Disease | completed | 10 |
| 2024-09-10 | P2 | Colgate Palmolive CL | NCT06565897 Clinical Investigation to Assess the Efficacy of Manual Toothbrushes in the Reduction of Plaque and Gingivitis. | Plaque, Dental; Gingivitis | completed | 84 |
| 2024-09-11 | P3 | BioRay Pharmaceutical Co., Ltd. | NCT04514419 Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | Breast Cancer | active not recruiting | 408 |
| 2024-09-11 | P2 | Hoffmann-La Roche | NCT04777331 A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | Parkinsons Disease | active not recruiting | 586 |
| 2024-09-11 | P3 | Biogen BIIB | NCT05083923 A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | Relapsing Forms of Multiple Sclerosis | completed | 136 |
| 2024-09-11 est. | P3 | Lambda Therapeutic Research Ltd. | NCT05419427 Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis | Osteoporosis, Postmenopausal | unknown | 552 |
| 2024-09-11 | P3 | BioCryst Pharmaceuticals BCRX | NCT05453968 Berotralstat Treatment in Children With Hereditary Angioedema | Hereditary Angioedema; Pediatric | active not recruiting | 29 |
| 2024-09-12 | P2/P3 | Neurim Pharmaceuticals Ltd. | NCT05267535 Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease | Alzheimer's Disease | terminated | 216 |
| 2024-09-12 | P3 | AbbVie ABBV | NCT05316233 JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance | Neck Lines | completed | 159 |
| 2024-09-12 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05522439 A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype | Asthma With Eosinophilic Phenotype | completed | 85 |
| 2024-09-12 | P1/P2 | Bristol-Myers Squibb BMY | NCT05543629 A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | Advanced Solid Tumors; Non-small Cell Lung Cancer | terminated | 36 |
| 2024-09-12 | P1/P2 | Oncternal Therapeutics, Inc | NCT05588440 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Relapsed/Refractory Aggressive B-Cell Malignancies | terminated | 9 |
| 2024-09-12 | P1/P2 | Oncternal Therapeutics, Inc | NCT05917470 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | Metastatic Castration-resistant Prostate Cancer | terminated | 21 |
| 2024-09-13 | P2 | AstraZeneca AZN | NCT03334617 Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | Non-Small Cell Lung Cancer | active not recruiting | 528 |
| 2024-09-13 | P1/P2 | Arvinas Estrogen Receptor, Inc. ARVN | NCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | completed | 219 |
| 2024-09-13 | P2/P3 | argenx ARGX | NCT05267600 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | completed | 98 |
| 2024-09-13 | P2/P3 | Bristol-Myers Squibb BMY | NCT05470985 A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an | Crohn Disease | terminated | 5 |
| 2024-09-13 | P2 | Biotheus Inc. | NCT05756972 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 64 |
| 2024-09-13 | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05770609 A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis | Mild to Moderate Ulcerative Colitis | completed | 53 |
| 2024-09-13 | P3 | AbbVie ABBV | NCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants | Forehead Lines | completed | 140 |
| 2024-09-13 | P2 | Pfizer PFE | NCT06237049 A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults | Influenza, Human; SARS-CoV-2 Infection; COVID-19 | completed | 644 |
| 2024-09-13 | P2 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06973681 A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects | Overweight or Obesity | completed | 120 |
| 2024-09-13 | P1/P2 | Applied Cognition | NCT07432997 Pharmacological Enhancement of Glymphatic Function in Humans | Alzheimer Disease | completed | 31 |
| 2024-09-15 | P3 | Amgen AMGN | NCT05724199 A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe At | Atopic Dermatitis | completed | 746 |
| 2024-09-15 est. | P2 | DermBiont, Inc. | NCT06108024 A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis | Seborrheic Keratosis | unknown | 60 |
| 2024-09-15 | P3 | Shanghai Institute Of Biological Products | NCT06399003 Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months | Measles-Mumps-Rubella | completed | 1200 |
| 2024-09-16 | P2 | Oculis OCS | NCT04762017 OCS-05 in Patients With Optic Neuritis | Optic Neuritis | completed | 36 |
| 2024-09-16 | P1/P2 | Criterium, Inc. | NCT04791384 Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | Breast Cancer | terminated | 5 |
| 2024-09-16 | P2 | ImmuneSensor Therapeutics Inc. | NCT05846646 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | Oligometastatic Disease | terminated | 6 |
| 2024-09-16 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05919823 A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Schizophrenia | completed | 202 |
| 2024-09-16 | P3 | Cipla Ltd. | NCT06154304 BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma | Bronchial Asthma | completed | 120 |
| 2024-09-17 | P1/P2 | Miltenyi Biomedicine GmbH | NCT03664635 MB-CART20.1 Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; B-cell Lymphoma Refrac | completed | 10 |
| 2024-09-17 | P2 | Shionogi | NCT04215991 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants | Gram-negative Bacterial Infections; Hospital Acquired Bacterial Pneumonia (HABP); Complicated Urinar | completed | 91 |
| 2024-09-17 | P3 | Boehringer Ingelheim | NCT04846868 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) | Schizophrenia | completed | 620 |
| 2024-09-17 | P3 | AbbVie ABBV | NCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment W | Hepatitis C Virus (HCV) | completed | 286 |
| 2024-09-17 | P3 | Janssen Research & Development, LLC | NCT06143878 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 774 |
| 2024-09-18 | P1/P2 | Transgene | NCT03260023 Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV | active not recruiting | 143 |
| 2024-09-18 est. | P2 | Biogen BIIB | NCT04079088 Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | withdrawn | |
| 2024-09-18 | P3 | EMD Serono Research & Development Institute, Inc. | NCT04459715 A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants W | Squamous Cell Carcinoma of the Head and Neck | terminated | 730 |
| 2024-09-18 | P3 | Janssen Research & Development, LLC | NCT05455684 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response | Depressive Disorder, Major; Anhedonia | completed | 513 |
| 2024-09-18 | P2 | Lallemand Health Solutions | NCT05755256 The Impact of Probiotics on Skin Hydration in Youth with Mild Acne | Acne Vulgaris; Hydration Acne | completed | 58 |
| 2024-09-18 | P3 | Bayer | NCT05915026 A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast | Contrast Enhancement in Magnetic Resonance Imaging; Children | completed | 105 |
| 2024-09-18 | P2 | Biosion, Inc. | NCT05932654 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | completed | 22 |
| 2024-09-18 | P1/P2 | BioNTech SE BNTX | NCT06069778 Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | Pancreatic Cancer | terminated | 1 |
| 2024-09-19 | P3 | Corcept Therapeutics CORT | NCT04308590 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas | Hypercortisolism | completed | 137 |
| 2024-09-19 | P3 | Cristcot HCA LLC | NCT04469686 Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories | Ulcerative Proctitis | completed | 200 |
| 2024-09-19 | P3 | Bio Sidus SA | NCT05843916 Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease | Fabry Disease | completed | 20 |
| 2024-09-19 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06538272 Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiv | CIPN - Chemotherapy-Induced Peripheral Neuropathy | completed | 210 |
| 2024-09-20 | P3 | AbbVie ABBV | NCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia | Schizophrenia | terminated | 34 |
| 2024-09-20 | P3 | BioDlink Biopharm Co., Ltd. | NCT05461339 TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration | active not recruiting | 488 |
| 2024-09-20 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05508659 A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | Advanced Solid Tumors | unknown | 128 |
| 2024-09-20 | P2 | Bolt Biotherapeutics, Inc. BOLT | NCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Metastatic Breast Cancer; HER2-positive Breast Cancer | terminated | 11 |
| 2024-09-20 | P3 | Pfizer PFE | NCT06473519 A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. | Respiratory Syncytial Virus (RSV) | completed | 453 |
| 2024-09-20 | P3 | Colgate Palmolive CL | NCT06954779 Arginine Plaque Metabolism Pilot Clinical Study | Plaque, Dental | completed | 20 |
| 2024-09-23 | P3 | AstraZeneca AZN | NCT04851964 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis | Chronic Rhinosinusitis With Nasal Polyps | completed | 416 |
| 2024-09-23 | P1/P2 | Cytovation AS | NCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers | Advanced Head and Neck Squamous Cell Carcinoma; Advanced Breast Cancer; Advanced Melanoma | completed | 6 |
| 2024-09-23 | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05520177 A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss | Branch Retinal Vein Occlusion | completed | 351 |
| 2024-09-23 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05741528 An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP | Schizophrenia | completed | 75 |
| 2024-09-23 | P3 | Abbisko Therapeutics Co, Ltd | NCT05804045 Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath | active not recruiting | 94 |
| 2024-09-24 | P3 | NovoCure GmbH NVCR | NCT02973789 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Foll | Nonsmall Cell Lung Cancer; NSCLC | completed | 291 |
| 2024-09-24 | P2 | FluidAI Medical | NCT04582708 Use of NERv's Inline Device as an Early Diagnostic Method for Postoperative Complications | Anastomotic Leak; Fistula; Postoperative Leak; Postoperative Pancreatic Fistula; POPF | completed | 316 |
| 2024-09-24 | P2 | Aardvark Therapeutics, Inc. AARD | NCT05153434 A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | completed | 19 |
| 2024-09-24 | P3 | Merck Sharp & Dohme LLC MRK | NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metast | Metastatic Non-Small Cell Lung Cancer | terminated | 739 |
| 2024-09-24 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT05966272 Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects | Type 2 Diabetes | completed | 199 |
| 2024-09-24 | P2/P3 | POLYSAN Scientific & Technological Pharmaceutical Company | NCT06183242 Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis | Cholestasis, Intrahepatic | completed | 328 |
| 2024-09-25 | P1/P2 | Oncternal Therapeutics, Inc | NCT03088878 A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | B-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone | completed | 95 |
| 2024-09-25 | P3 | Biohaven Pharmaceuticals, Inc. BHVN | NCT05337553 A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy; Neuromuscular Diseases; SMA | active not recruiting | 269 |
| 2024-09-25 | P2 | Takeda TAK | NCT05814016 A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery | Sleep Apnea | terminated | 41 |
| 2024-09-25 | P3 | Vifor Fresenius Medical Care Renal Pharma | NCT05885737 Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus | Uremic Pruritus | completed | 260 |
| 2024-09-25 | P3 | NewAmsterdam Pharma NAMS | NCT06005597 Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterol | completed | 407 |
| 2024-09-25 | P2 | HysensBio Co., Ltd | NCT06264453 A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity | Dentin Hypersensitivity | completed | 171 |
| 2024-09-25 | P2 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | NCT07186387 Study of LW402 in Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 144 |
| 2024-09-26 | P2 | Novo Nordisk A/S NVO | NCT02616562 Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Tre | Growth Hormone Disorder; Growth Hormone Deficiency in Children | completed | 76 |
| 2024-09-26 | P1/P2 | Hoffmann-La Roche | NCT03280563 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast | Breast Neoplasms | completed | 144 |
| 2024-09-26 | P1/P2 | Achilles Therapeutics UK Limited | NCT04032847 ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Advanced Non Small Cell Lung Cancer | terminated | 27 |
| 2024-09-26 | P1/P2 | ApcinteX Ltd | NCT04073498 The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) | Hemophilia a; Hemophilia B | completed | 39 |
| 2024-09-26 | P2 | Windtree Therapeutics | NCT04325035 The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock | Cardiogenic Shock | completed | 90 |
| 2024-09-26 | P2 | Hope Medicine (Nanjing) Co., Ltd | NCT05101317 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain | Endometriosis | completed | 142 |
| 2024-09-26 | P3 | NewAmsterdam Pharma NAMS | NCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Atheroscleroti | completed | 2530 |
| 2024-09-26 | P2 | PTC Therapeutics PTC | NCT05349721 Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | Amyotrophic Lateral Sclerosis | terminated | 336 |
| 2024-09-26 | P2 | Cardior Pharmaceuticals GmbH | NCT05350969 Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction | Myocardial Infarction, Acute; Heart Failure, Left Sided | completed | 294 |
| 2024-09-26 | P2 | Janssen Research & Development, LLC | NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | completed | 252 |
| 2024-09-26 | P2 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT06226090 A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity | Obesity; Overweight | completed | 314 |
| 2024-09-26 | P3 | CanSino Biologics Inc. | NCT06226714 A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds | Meningococcal Meningitis | active not recruiting | 840 |
| 2024-09-27 | P3 | Merck Sharp & Dohme LLC MRK | NCT04776148 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-79 | Colorectal Neoplasms | completed | 563 |
| 2024-09-27 | P2 | Thiogenesis Therapeutics, Inc. TTIPF | NCT05212662 Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19 | COVID-19; COVID-19 Acute Respiratory Distress Syndrome | withdrawn | |
| 2024-09-27 | P2 | Akeso | NCT05227651 AK104 in Neoadjuvant Treatment of Cervical Cancer | Cervical Cancer | completed | 14 |
| 2024-09-27 | P2/P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT05523895 Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder | completed | 237 |
| 2024-09-27 | P3 | Tonghua Anrate Biopharmaceutical Co., Ltd. | NCT06911554 A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites | Hepatic Ascites | completed | 416 |
| 2024-09-27 | P2 | Shenzhen Sciencare Medical Industries Co., Ltd. | NCT07333638 Phase II Clinical Study on the Efficacy and Safety of Naltrexone Implant in Patients With Alcohol Use Disorder | AUD | completed | 210 |
| 2024-09-27 | P3 | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | NCT07790159 Budesonide/Formoterol Inhalation Powder in Adults With Asthma | Asthma | completed | 338 |
| 2024-09-29 | P1/P2 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT04563533 Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) | Acute Gastroenteritis | completed | 580 |
| 2024-09-29 | P2 | Novartis Pharmaceuticals NVS | NCT04864392 Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis | Osteoarthritis | terminated | 576 |
| 2024-09-29 | P3 | Evopoint Biosciences Inc. | NCT05204563 Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) | Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | completed | 450 |
| 2024-09-30 | P1/P2 | Seagen Inc. | NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Triple Negative Breast Neoplasms | completed | 185 |
| 2024-09-30 | P2 | TaiRx, Inc. | NCT03600233 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumor; Gastro-enteropancreatic Neuroendocrine Tumor | active not recruiting | 34 |
| 2024-09-30 | P1/P2 | Microvascular Therapeutics, LLC | NCT03882359 An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers | Heart Diseases | completed | 16 |
| 2024-09-30 | P3 | Eurofarma Laboratorios S.A. | NCT03936933 Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer | Breast Cancer | terminated | 6 |
| 2024-09-30 | P1/P2 | Taiho Oncology, Inc. | NCT04657081 Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | active not recruiting | 101 |
| 2024-09-30 | P3 | MeiraGTx Ocular UK Ltd MGTX | NCT04671433 Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | X-Linked Retinitis Pigmentosa | completed | 105 |
| 2024-09-30 | P1/P2 | Famewave Ltd. | NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | Solid Tumor; Non Small Cell Lung Cancer; Pancreatic Cancer; Ovarian Cancer; Papillary Thyroid Cancer | completed | 79 |
| 2024-09-30 est. | P3 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT04852068 A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) | Rabies Vaccine Adverse Reaction; Safety and Efficacy | unknown | 2480 |
| 2024-09-30 est. | P2 | Hallux, Inc. | NCT05135910 To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis | Onychomycosis of Toenail | unknown | 35 |
| 2024-09-30 | P3 | Stealth BioTherapeutics Inc. | NCT05162768 Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) | Mitochondrial Myopathies; Mitochondrial Pathology; Mitochondrial DNA Mutation; Mitochondrial Disease | completed | 102 |
| 2024-09-30 est. | P2 | Shanghai Kechow Pharma, Inc. | NCT05263453 HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | Melanoma | unknown | 104 |
| 2024-09-30 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT05466643 A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | unknown | 240 |
| 2024-09-30 est. | P2 | Shanghai Henlius Biotech | NCT05513573 Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatm | Nasopharyngeal Carcinoma by AJCC V8 Stage | unknown | 75 |
| 2024-09-30 | P2/P3 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT05555706 Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | completed | 62 |
| 2024-09-30 | P2 | Guerbet | NCT05590884 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age | Central Nervous System Diseases; Pediatric Disorder; Body Indication | completed | 36 |
| 2024-09-30 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06006104 Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | Advanced Prostate Cancer | unknown | 49 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06071936 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Periphera | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06071949 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central N | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06071962 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Back Pain; Lower Back Pain; | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06071975 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Diabetes; Diabetic Neuropat | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06071988 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Periphera | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06072001 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central N | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06072560 Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Back Pain; Lower Back Pain; | unknown | 558 |
| 2024-09-30 est. | P3 | Apurano Pharmaceuticals GmbH | NCT06072573 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | Pain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Diabetes; Diabetic Neuropat | unknown | 558 |
| 2024-09-30 | P2/P3 | Pfizer PFE | NCT06079320 A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection | Respiratory Syncytial Virus Infection | terminated | 16 |
| 2024-09-30 | P2 | Endo USA Inc., a Keenova Therapeutics Company | NCT06169319 A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) | Plantar Fasciitis | completed | 231 |
| 2024-09-30 | P2 | AstraZeneca AZN | NCT06173570 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia | Dyslipidemia | completed | 428 |
| 2024-09-30 | P2 | Dexa Medica Group | NCT06497439 Efficacy and Safety of Silfamin for Common Cold | Common Cold; Sore-throat | completed | 60 |
| 2024-09-30 | P2 | Dexa Medica Group | NCT06510257 Safety and Efficacy Reconyl for Cough With/Without Sore Throat | Cough | completed | 60 |
| 2024-09-30 est. | P1/P2 | Synthonics Inc | NCT06570941 Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome | Restless Legs Syndrome | unknown | 10 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.